F10 and atrial fibrillation: For example, the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial recruited from 1,178 centres (45 countries) a total of 13,997 participants, with the majority (83%) being White (other categories were 13% Asians, 1% Black and 3% other) (Piccini et al., 2014; Lee et al., 2021).